MA52148A - Peptides chimères pour administration d'antisens - Google Patents
Peptides chimères pour administration d'antisensInfo
- Publication number
- MA52148A MA52148A MA052148A MA52148A MA52148A MA 52148 A MA52148 A MA 52148A MA 052148 A MA052148 A MA 052148A MA 52148 A MA52148 A MA 52148A MA 52148 A MA52148 A MA 52148A
- Authority
- MA
- Morocco
- Prior art keywords
- chimères
- antisens
- peptides
- administration
- peptides chimères
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862644202P | 2018-03-16 | 2018-03-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52148A true MA52148A (fr) | 2021-01-20 |
Family
ID=67908050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052148A MA52148A (fr) | 2018-03-16 | 2019-03-15 | Peptides chimères pour administration d'antisens |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210260206A1 (fr) |
EP (1) | EP3765030A4 (fr) |
JP (1) | JP2021518361A (fr) |
MA (1) | MA52148A (fr) |
TW (1) | TW202002990A (fr) |
WO (1) | WO2019178479A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3697422A4 (fr) * | 2017-10-17 | 2021-08-11 | Sarepta Therapeutics, Inc. | Peptides de pénétration cellulaire pour administration antisens |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1282699B1 (fr) * | 2000-05-04 | 2012-11-21 | Sarepta Therapeutics, Inc. | Composition anti-sens a region d'epissage et methode associee |
US8129352B2 (en) * | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
DK2024499T3 (da) * | 2006-05-10 | 2018-01-29 | Sarepta Therapeutics Inc | Oligonukleotidanaloger med kationiske intersubunit-koblinger |
US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
EP2283029A1 (fr) * | 2008-06-04 | 2011-02-16 | Medical Research Council | Peptides |
WO2013017631A1 (fr) * | 2011-08-04 | 2013-02-07 | Msd Oss B.V. | Conjugué kisspeptide-pentasaccharide |
EA032088B1 (ru) * | 2011-10-27 | 2019-04-30 | Массачусетс Инститьют Оф Текнолоджи | Аминокислотные производные, функционализованные на n-конце, способные образовывать микросферы, инкапсулирующие лекарственное средство |
US9944926B2 (en) * | 2011-11-30 | 2018-04-17 | Sarepta Therapeutics, Inc. | Induced exon inclusion in spinal muscle atrophy |
JP6404219B2 (ja) * | 2012-09-25 | 2018-10-10 | ジェンザイム・コーポレーション | 筋強直性ジストロフィーを治療するためのペプチド結合モルホリノアンチセンスオリゴヌクレオチド |
WO2014124952A1 (fr) * | 2013-02-12 | 2014-08-21 | Syddansk Universitet | Oligonucléotides alcyne-lna pouvant être traités par "chimie click" |
EP2970964B8 (fr) * | 2013-03-14 | 2019-03-06 | Sarepta Therapeutics, Inc. | Compositions de sauts d'exon pour le traitement de la dystrophie musculaire |
WO2014144978A2 (fr) * | 2013-03-15 | 2014-09-18 | Sarepta Therapeutics, Inc. | Compositions améliorées pour le traitement de la dystrophie musculaire |
US11371994B2 (en) * | 2013-09-13 | 2022-06-28 | California Institute Of Technology | Phosphorylated Akt-specific capture agents, compositions, and methods of using and making |
WO2017066789A1 (fr) * | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Analogues de coiffe d'arnm avec sucre modifié |
EP3697422A4 (fr) * | 2017-10-17 | 2021-08-11 | Sarepta Therapeutics, Inc. | Peptides de pénétration cellulaire pour administration antisens |
-
2019
- 2019-03-15 EP EP19767585.3A patent/EP3765030A4/fr active Pending
- 2019-03-15 JP JP2020549641A patent/JP2021518361A/ja active Pending
- 2019-03-15 TW TW108108833A patent/TW202002990A/zh unknown
- 2019-03-15 MA MA052148A patent/MA52148A/fr unknown
- 2019-03-15 US US16/981,145 patent/US20210260206A1/en active Pending
- 2019-03-15 WO PCT/US2019/022475 patent/WO2019178479A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP2021518361A (ja) | 2021-08-02 |
WO2019178479A1 (fr) | 2019-09-19 |
TW202002990A (zh) | 2020-01-16 |
EP3765030A4 (fr) | 2022-01-26 |
US20210260206A1 (en) | 2021-08-26 |
EP3765030A1 (fr) | 2021-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
MA52198A (fr) | Systèmes et méthodes pour l'administration retardée de médicament | |
MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
MA50522A (fr) | Nanoparticules lipidiques pour l'administration d'un arn modifié codant pour un polypeptide vegf-a | |
MA51066A (fr) | Inhibiteurs d'intégrine | |
MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
MA45472A (fr) | Systèmes d'administration pour la libération contrôlée de médicaments | |
DK3875085T3 (da) | Edaravon-suspension til oral indgivelse | |
MA43587A (fr) | Arnm thérapeutiques codant pour des anticorps anti-ctla-4 | |
FR3056552B1 (fr) | Harpon d'ancrage externe pour aeronef | |
MA53924A (fr) | Modulateurs de l'expression d'apol1 | |
ZA202006264B (en) | Stable formulations of therapeutic antibody | |
MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
MA51795A (fr) | Oligonucléotides pour moduler l'expression de tmem106b | |
IL279622A (en) | Pharmaceutical formulations of masked antibodies | |
MA53238A (fr) | Formules d'ag10 | |
MA53551A (fr) | Dosage nocturne chronique de lasmiditan pour la prévention de la migraine | |
MA49278A (fr) | Oligonucléotides antisens pour moduler l'expression de htra1 | |
MA52148A (fr) | Peptides chimères pour administration d'antisens | |
DK3804606T3 (da) | Oftalmisk billeddannelsessystem | |
MA50156A (fr) | Variants d'anticorps | |
MA45227A (fr) | Peptides pour le traitement de l'ostéoarthrite | |
IL281720A (en) | HMGB1 protein derivatives to remove biofilms | |
DK4076404T3 (da) | Farmaceutisk pyrazolsammensætning |